Business
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRV...
About this update from Marvel Biosciences Corp
[{"type":"text","content":"Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204\nCALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that it has selected Novotech as the contract research organization (“CRO”) for the Company’s upcoming Phase I for its lead drug candidate MB-204. Novotech is an internationally recognized full service CRO based in Australia, that was awarded the 2025 Global Biotechnology Contract Research Organization Company of the Year by Frost & Sullivan in recognition of its innovation, client-focused delivery, and global impact. “Having previously worked with Novotech on multiple clinical programs, I am pleased to be working with Novotech again”, said Dr. Mark Williams, CSO of Marvel Biosciences. “Australia is an attractive place to conduct first-in-man studies owing to their favourable regulatory environment and tax credits exceeding 40% of the costs incurred there.” MB-204 is Marvel’s patented neuroactive adenosine A2A antagonist that has completed cGMP synthesis and 4-week GLP toxicological studies. MB-204 is being developed for neurodevelopmental disorders such as Rett syndrome and Fragile X with the potential to treat autism spectrum disorder and depression. Selecting a leading Australian CRO positions Marvel Biosciences to accelerate its Phase I program through a streamlined regulatory pathway with significant cost efficiencies, maximizing capital while maintaining world-class clinical standards. Partnering with Novotech marks a pivotal inflection point for the Company, signaling MB-204’s transition into human trials and reinforcing confidence in its potential to deliver value in underserved neurodevelopmental indications. About Marvel Biosciences Corp. Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Our lead drug candidate, MB-204, is a novel fluorinated deriva...